Advertisement

Forced Degradation and Its Relation to Real Time Drug Product Stability

  • Steven W. Baertschi
Chapter
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume XII)

Abstract

Forced degradation (stress testing) studies are fundamental to the developing stability-indicating analytical methods as part of the overall analytical control strategy. Stress testing studies conducted on both the drug substance and product are useful for gaining an understanding of the degradation chemistry of a drug. The degradation products observed in such studies are “potential” degradation products that may or may not be formed under relevant storage conditions, but these products reveal the degradation pathways available to the drug and facilitate the development of stability-indicating analytical methods. These methods can then used to monitor drug stability during long-term stability studies to determine which products actually form under room temperature and accelerated stability conditions. In this presentation, the foundational aspects of forced degradation studies and their relationship Quality by Design principles will be presented along with critical aspects predicting the “real time” drug stability and degradation profiles will be discussed.

Keywords

Stress Testing Design Space Rose Bengal Knowledge Space Intrinsic Stability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Bernard A. Olsen is gratefully acknowledged for helpful discussions and expert review of the content of this chapter.

References

  1. Baertschi SW (2006) Analytical methodologies for discovering and profiling degradation-related impurities. TrAC Trends Analyt Chem 25(8):758–767CrossRefGoogle Scholar
  2. Baertschi SW, Nussbaum MA, Jansen PJ (2005) Role of “mass balance” in pharmaceutical stress testing. In: Baertschi SW (ed) Pharmaceutical stress testing: predicting drug degradation, vol 153. Taylor & Francis, New York, pp 181–204Google Scholar
  3. Baertschi SW, Jansen PJ et al. (2006) Presented at the Institute for International Research conference on Forced Degradation, Short Hills, NJGoogle Scholar
  4. Boccardi G (2005) Oxidative susceptibility testing. In: Baertschi S (ed) Pharmaceutical stress testing: predicting drug degradation. Taylor & Francis, New York, pp 223–225Google Scholar
  5. Boccardi G, Deleuze C, Gachon M, Palmisano G, Vergnaud JP (1992) Autoxidation of tetrazepam in tablets: prediction of degradation impurities from the oxidative behavior in solution. J Pharm Sci 81(2):183–185CrossRefPubMedGoogle Scholar
  6. Brustugun J, Tonnesen HH, Klem W, Kjonniksen I (2000) Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation. PDA J Pharm Sci Technol 54:136–143PubMedGoogle Scholar
  7. Guerrieri P, Salameh A, Taylor L (2007) Effect of small levels of impurities on the water vapor sorption behavior of ranitidine HCl. Pharm Res 24(1):147–156CrossRefPubMedGoogle Scholar
  8. International Conference on Harmonization (1997) Guideline for the photostability testing of new drug substances and products, stability testing of new drug substances and products, Q1B, November 1997Google Scholar
  9. International Conference on Harmonization (2003) Stability testing of new drug substances and products, Q1A (R2), August 2003Google Scholar
  10. International Conference on Harmonization (2006a) Guidance for industry: pharmaceutical development, Q8, May 2006Google Scholar
  11. International Conference on Harmonization (2006b) Pharmaceutical development, Q8 Annex, November 2006Google Scholar
  12. Jansen PJ, Smith KW, Baertschi SW (2005) Stress testing: analytical considerations. In: Baertschi SW (ed) Pharmaceutical stress testing: predicting drug degradation, vol 153. Taylor & Francis, New York, pp 141–171Google Scholar
  13. Nishinaga A, Shinizu T (1980) Base-catalyzed oxygenation of tert-butylated phenols, 4. Mechanism of base-catalyzed ortho regioselective dioxygen incorporation into 4-aryl-2, 6-di-tert-butylphenols. J org chan 45(24): 4997–4998Google Scholar
  14. Olsen BA, Baertschi SW (2003) Strategies for investigation and control of process- and degradation-related impurities. In: Ahuja S, Alsante KM (eds) Handbook of isolation and characterization in pharmaceuticals. Academic, New York, pp 89–117Google Scholar
  15. Reed RA, Harmon P, Manas D, Wasylaschuk W, Galli C, Biddell R, Bergquist PA, Hunke W, Templeton AC, Ip D (2003) The role of excipients and package components in the photostability of liquid formulations. PDA J Pharm Sci Technol 57(5):351–368PubMedGoogle Scholar
  16. Salameh AK, Taylor LS (2005) Deliquescence in binary mixtures. Pharm Res 22(2):318–324CrossRefPubMedGoogle Scholar
  17. Seburg RA, Ballard JM, Hwang T-L, Sullivan CM (2006) Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation. J Pharm Biomed Anal 42(4):411–422CrossRefPubMedGoogle Scholar
  18. Thatcher SR, Baertschi SW, Mansfield RK, Miller RB, Davis CW (2001a) Pharmaceutical photostability: a technical guide and practical interpretation of the ICH guideline and its application to pharmaceutical stability – Part 1. Pharm Technol 25(3):98–110Google Scholar
  19. Thatcher SR, Mansfield RK, Davis CW, Baertschi SW (2001b) Pharmaceutical photostability. A technical guide and practical interpretation of the ICH guideline and its application to pharmaceutical stability. Part II. Pharm Technol 25(4):50–62Google Scholar
  20. Wasylaschuk WR, Harmon PA, Wagner G, Harman AB, Templeton AC, Xu H, Reed RA (2007) Evaluation of hydroperoxides in common pharmaceutical excipients. J Pharm Sci 96(1):106–116CrossRefPubMedGoogle Scholar
  21. Waterman KC, Adami RC, Hong J (2003) Impurities in drug products. In: Ahuja S, Alsante KM (eds) Handbook of isolation and characterization of impurities in pharmaceuticals. Academic, New York, pp 75–88Google Scholar
  22. Zahn M (2006) Temperature control and product quality of medicines in transit, Barcelona, 27–28 Sept 2006, pp 731–736Google Scholar
  23. Zahn M, Kållberg PW, Slappendel GM, Smeenge HM (2006) A risk-based approach to establish stability testing conditions for tropical countries. J Pharm Sci 95(5):946–965CrossRefPubMedGoogle Scholar
  24. Zannou EA, Ji Q, Joshi YM, Serajuddin ATM (2007) Stabilization of the maleate salt of a basic drug by adjustment of microenvironmental pH in solid dosage form. Int J Pharm 337(1–2):210–218CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  1. 1.Eli Lilly and Company, Lilly Research LaboratoriesIndianapolisUSA

Personalised recommendations